ProCE Banner Activity

BTK Inhibitors for Mantle Cell Lymphoma: Overview and Current Treatment Landscape

Slideset

Download these slides for a brief overview of the initial data on the use of BTK inhibitors for patients with mantle cell lymphoma (MCL), with a focus on the mechanism of action, initial trial data in relapsed/refractory MCL, and important considerations for addressing adverse events associated with BTKi therapy and assessing individuals for adherence to BTKi regimens.

Released: December 05, 2024

Expiration: December 04, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca